Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Common Equity (2016 - 2025)

Acro Biomedical has reported Common Equity over the past 10 years, most recently at -$386964.0 for Q4 2025.

  • Quarterly results put Common Equity at -$386964.0 for Q4 2025, down 31.19% from a year ago — trailing twelve months through Dec 2025 was -$386964.0 (down 31.19% YoY), and the annual figure for FY2025 was -$386964.0, down 31.19%.
  • Common Equity for Q4 2025 was -$386964.0 at Acro Biomedical, up from -$432619.0 in the prior quarter.
  • Over the last five years, Common Equity for ACBM hit a ceiling of $643707.0 in Q4 2021 and a floor of -$432619.0 in Q3 2025.
  • Median Common Equity over the past 5 years was $50020.5 (2023), compared with a mean of $118319.2.
  • Biggest five-year swings in Common Equity: grew 2.28% in 2022 and later crashed 181.38% in 2024.
  • Acro Biomedical's Common Equity stood at $643707.0 in 2021, then fell by 24.44% to $486370.0 in 2022, then plummeted by 152.84% to -$257014.0 in 2023, then decreased by 14.77% to -$294972.0 in 2024, then crashed by 31.19% to -$386964.0 in 2025.
  • The last three reported values for Common Equity were -$386964.0 (Q4 2025), -$432619.0 (Q3 2025), and -$317520.0 (Q2 2025) per Business Quant data.